There was evidence of heterogeneity in the association of IGFBP-2 with overall prostate cancer by BMI (Phet = 0.0007); for men whose BMI was <25 kg/m2 at baseline, IGFBP-2 was inversely associated with prostate cancer (0.89: 0.83, 0.96), and the OR for men with BMI 30+ was 1.19 (0.99, 1.42) (Supplementary Figure S7). Here, IGFBP2 is linked to prostate carcinoma.